1. Metabolic Enzyme/Protease Autophagy Apoptosis Anti-infection
  2. Proteasome Autophagy Mitophagy Apoptosis Endogenous Metabolite Antibiotic Bacterial
  3. Celastrol

Celastrol  (Synonyms: 雷公藤红素; Tripterine; Tripterin)

目录号: HY-13067 纯度: 99.68%
COA 产品使用指南 技术支持

Celastrol (Tripterine) 是一种蛋白酶体抑制剂,有效且优先抑制 20S 蛋白酶体的胰凝乳蛋白酶样活性,IC50 为 2.5 μM。此外,Celastrol 也是一种对标准和临床 methicillin-resistant Staphylococcus aureus (MRSA) 菌株具有强大抗菌活性的抗生素 (antibiotic),通过与 P5CDH 结合诱导氧化应激并抑制 DNA 合成。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Celastrol Chemical Structure

Celastrol Chemical Structure

CAS No. : 34157-83-0

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 价格 是否有货 数量
5 mg ¥523
In-stock
10 mg ¥837
In-stock
25 mg ¥1538
In-stock
50 mg ¥2278
In-stock
100 mg ¥3255
In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of Celastrol:

MCE 顾客使用本产品发表的 38 篇科研文献

WB

    Celastrol purchased from MCE. Usage Cited in: Cell Death Dis. 2018 May 22;9(6):601.  [Abstract]

    Serum-starved HK-2 cells are pretreated with or without indicated concentrations of Celastrol (CEL) for 1 h and then stimulated with TGF-β1 (10 ng/mL) for 24 h. Representative western blots and quantification data of CB2R expression in HK-2 cells are presented.

    Celastrol purchased from MCE. Usage Cited in: Life Sci. 2018 Jul 15;205:136-144.  [Abstract]

    Effects of Celastrol (CEL) on the expression of F4/80 in plantar skin. CEL treatment suppresses macrophage expression in plantar skin. Western blot assay shows significantly downregulated F4/80 levels in 10 and 20 μg/paw CEL groups.

    Celastrol purchased from MCE. Usage Cited in: RSC Adv. 2016,6, 42537-42544.

    Celastrol is able to increase HSP70 protein expression by more than 1.8-fold in PC-3 cells after 24 h of incubation.

    Celastrol purchased from MCE. Usage Cited in: Mol Biosyst. 2016 Dec 20;13(1):83-91.  [Abstract]

    Validation of selected targets of Celastrol identified by competitive proteomics. Western blotting (by using anti-GSTO1 and anti-PDI antibodies) of the pull-down samples upon labeling with IA-yne.
    • 生物活性

    • 实验参考方法

    • 纯度 & 产品资料

    • 参考文献

    生物活性

    Celastrol (Tripterine;Tripterin) is a proteasome inhibitor which potently and preferentially inhibits the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM. In addition, Celastrol is also an antibiotic with potent antimicrobial activity against standard and clinical methicillin-resistant Staphylococcus aureus (MRSA) strains, inducing oxidative stress and inhibiting DNA synthesis by binding to P5CDH[1][2][3].

    IC50 & Target

    Human Endogenous Metabolite

     

    细胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    1A9 ED50
    0.091 μg/mL
    Compound: 6
    Cytotoxicity against human 1A9 cells after 3 days by SRB assay
    Cytotoxicity against human 1A9 cells after 3 days by SRB assay
    [PMID: 14640511]
    1A9 ED50
    0.11 μg/mL
    Compound: 6
    Cytotoxicity against human 1A9 cells after 6 days by SRB assay
    Cytotoxicity against human 1A9 cells after 6 days by SRB assay
    [PMID: 14640511]
    1A9/ptx-10 ED50
    0.1 μg/mL
    Compound: 6
    Cytotoxicity against human 1A9/PTX10 cells after 3 days by SRB assay
    Cytotoxicity against human 1A9/PTX10 cells after 3 days by SRB assay
    [PMID: 14640511]
    1A9/ptx-10 ED50
    0.11 μg/mL
    Compound: 6
    Cytotoxicity against human 1A9/PTX10 cells after 6 days by SRB assay
    Cytotoxicity against human 1A9/PTX10 cells after 6 days by SRB assay
    [PMID: 14640511]
    A 172 IC50
    2.31 μM
    Compound: CEL
    Antiproliferative activity against human A-172 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    Antiproliferative activity against human A-172 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    [PMID: 34968902]
    A2780 IC50
    1.84 μM
    Compound: Celastrol
    Antiproliferative activity against human A2780 cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human A2780 cells incubated for 48 hrs by MTT assay
    [PMID: 31279299]
    A-431 ED50
    2.4 μg/mL
    Compound: 3
    Cytotoxicity against human A431 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human A431 cells after 72 hrs by sulforhodamine B assay
    [PMID: 8158155]
    A549 IC50
    > 100 μM
    Compound: CEL
    Antiproliferative activity against human A549 cells expressing Hsp90-Cdc37 protein assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells expressing Hsp90-Cdc37 protein assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    [PMID: 35238566]
    A549 IC50
    > 100 μM
    Compound: CEL
    Antiproliferative activity against human A549 cells expressing Hsp90 protein assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells expressing Hsp90 protein assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    [PMID: 35238566]
    A549 IC50
    > 100 μM
    Compound: CEL
    Antiproliferative activity against human A549 cells expressing Cdc37 protein assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells expressing Cdc37 protein assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    [PMID: 35238566]
    A549 ED50
    0.25 μg/mL
    Compound: 6
    Cytotoxicity against human A549 cells after 3 days by SRB assay
    Cytotoxicity against human A549 cells after 3 days by SRB assay
    [PMID: 14640511]
    A549 IC50
    0.98 μM
    Compound: CEL
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay
    [PMID: 35290844]
    A549 IC50
    1.1 μM
    Compound: CEL
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 96 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 96 hrs by MTT assay
    [PMID: 35255689]
    A549 IC50
    1.28 μM
    Compound: CE
    Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 31051401]
    A549 IC50
    1.43 μM
    Compound: 1; CEL
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    [PMID: 30316059]
    A549 IC50
    1.48 μM
    Compound: CEL
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    [PMID: 31725288]
    A549 IC50
    1.56 μM
    Compound: 1
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    [PMID: 28865279]
    A549 IC50
    1.56 μM
    Compound: 1
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    [PMID: 28688281]
    A549 IC50
    1.68 μM
    Compound: CEL
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    [PMID: 35238566]
    A549 IC50
    1.8 μM
    Compound: Celastrol
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    [PMID: 34170694]
    A549 IC50
    2.01 μM
    Compound: Celastrol
    Antiproliferative activity against paclitaxel-resistant human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against paclitaxel-resistant human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 27647369]
    A549 IC50
    2.02 μM
    Compound: Celastrol
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 27647369]
    A549 IC50
    2.12 μM
    Compound: Celastrol
    Cytotoxic activity against human A549 cells incubated for 48 hrs by MTT assay
    Cytotoxic activity against human A549 cells incubated for 48 hrs by MTT assay
    [PMID: 28587825]
    A549 IC50
    2.83 μM
    Compound: 1
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    [PMID: 34256125]
    A549 IC50
    4.99 μM
    Compound: Celastrol
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 36274272]
    A549 IC50
    6.59 μM
    Compound: Celastrol
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
    [PMID: 29486954]
    A549 IC50
    690 nM
    Compound: 2
    Growth inhibition of human A549 cells measured every 2 hrs over 6 days by live cell imaging based method
    Growth inhibition of human A549 cells measured every 2 hrs over 6 days by live cell imaging based method
    [PMID: 28621943]
    BC1 cell line ED50
    0.3 μg/mL
    Compound: 3
    Cytotoxicity against human BC1 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human BC1 cells after 72 hrs by sulforhodamine B assay
    [PMID: 8158155]
    BEAS-2B IC50
    0.454 μM
    Compound: 1
    Antiproliferative activity against human BEAS-2B cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    Antiproliferative activity against human BEAS-2B cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    [PMID: 34256125]
    Bel-7402 IC50
    0.44 μM
    Compound: Celastrol
    Cytotoxic activity against human Bel7402 cells incubated for 48 hrs by MTT assay
    Cytotoxic activity against human Bel7402 cells incubated for 48 hrs by MTT assay
    [PMID: 28587825]
    Bel-7402 IC50
    1.81 μM
    Compound: CEL
    Antiproliferative activity against human Bel-7402 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay
    Antiproliferative activity against human Bel-7402 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay
    [PMID: 35290844]
    BGC-823 IC50
    1.1 μM
    Compound: CEL
    Antiproliferative activity against human BGC-823 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    Antiproliferative activity against human BGC-823 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    [PMID: 35536757]
    BJ IC50
    2.74 μM
    Compound: 1
    Antiproliferative activity against human BJ cells after 72 hrs by MTT assay
    Antiproliferative activity against human BJ cells after 72 hrs by MTT assay
    [PMID: 28865279]
    BJ IC50
    2.74 μM
    Compound: 1
    Cytotoxicity against human BJ cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human BJ cells assessed as reduction in cell viability after 72 hrs by MTT assay
    [PMID: 28688281]
    Col2 ED50
    0.4 μg/mL
    Compound: 3
    Cytotoxicity against human Col2 cells after 96 hrs by sulforhodamine B assay
    Cytotoxicity against human Col2 cells after 96 hrs by sulforhodamine B assay
    [PMID: 8158155]
    HCT-116 IC50
    1.81 μM
    Compound: CEL
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    [PMID: 35238566]
    HCT-116 IC50
    1.9 μM
    Compound: CEL
    Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    [PMID: 35536757]
    HCT-116 IC50
    5.26 μM
    Compound: Celastrol
    Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
    [PMID: 29486954]
    HCT-8 ED50
    0.23 μg/mL
    Compound: 6
    Cytotoxicity against human HCT8 cells after 3 days by SRB assay
    Cytotoxicity against human HCT8 cells after 3 days by SRB assay
    [PMID: 14640511]
    HEK-293T IC50
    0.67 μM
    Compound: 22
    Cytotoxicity against human 293T cells assessed as cell viability by dual-luciferase reporter assay
    Cytotoxicity against human 293T cells assessed as cell viability by dual-luciferase reporter assay
    [PMID: 21393004]
    HeLa IC50
    0.15 μM
    Compound: celastrol
    Inhibition of NF-kappaB activity in human HeLa cells by SEAP reporter assay
    Inhibition of NF-kappaB activity in human HeLa cells by SEAP reporter assay
    [PMID: 20469887]
    HeLa IC50
    0.15 μM
    Compound: Celastrol
    Inhibition of TNF-alpha-induced NF-kappaB activation in human HeLa cells by SEAP reporter gene assay
    Inhibition of TNF-alpha-induced NF-kappaB activation in human HeLa cells by SEAP reporter gene assay
    [PMID: 18841906]
    HeLa IC50
    0.72 μg/mL
    Compound: Celastrol
    Inhibition of TNFalpha-induced NF-kappaB activity (unknown origin) expressed in HeLa cells cotreated with compound and 10 ng/ml TNF-alpha for 24 hr by reporter gene assay
    Inhibition of TNFalpha-induced NF-kappaB activity (unknown origin) expressed in HeLa cells cotreated with compound and 10 ng/ml TNF-alpha for 24 hr by reporter gene assay
    10.1007/s00044-010-9409-z
    HeLa IC50
    0.84 μM
    Compound: Celastrol
    Cytotoxic activity against human HeLa cells incubated for 48 hrs by MTT assay
    Cytotoxic activity against human HeLa cells incubated for 48 hrs by MTT assay
    [PMID: 28587825]
    HeLa EC50
    1.1 μM
    Compound: Celastrol
    Amplification of HSF1 transcriptional activity in human heat shock-induced HeLa cells assessed as granule formation treated 1 hr before heat shock challenge measured after 2 hrs without recovery time by immunocytochemical staining
    Amplification of HSF1 transcriptional activity in human heat shock-induced HeLa cells assessed as granule formation treated 1 hr before heat shock challenge measured after 2 hrs without recovery time by immunocytochemical staining
    [PMID: 19502057]
    HeLa IC50
    1.21 μM
    Compound: Celastrol
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 36274272]
    HeLa IC50
    1.7 μM
    Compound: CEL
    Antiproliferative activity against human HeLa cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    [PMID: 35536757]
    HeLa EC50
    2.6 μM
    Compound: Celastrol
    Amplification of HSF1 transcriptional activity in human HeLa cells assessed as granule formation pretreated for 3 hrs by immunocytochemical staining
    Amplification of HSF1 transcriptional activity in human HeLa cells assessed as granule formation pretreated for 3 hrs by immunocytochemical staining
    [PMID: 19502057]
    HeLa CC50
    3 μM
    Compound: Celastrol
    Cytotoxicity against human HeLa cells after 72 hrs by MTS assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTS assay
    [PMID: 19502057]
    Hep 3B2 IC50
    0.76 μM
    Compound: Celastrol
    Cytotoxicity against human Hep3B cells assessed as reduction in cell viability incubated for 24 hrs under normaxic condition by MTT assay
    Cytotoxicity against human Hep3B cells assessed as reduction in cell viability incubated for 24 hrs under normaxic condition by MTT assay
    [PMID: 33930802]
    HepG2 IC50
    0.58 μM
    Compound: Celastrol
    Cytotoxic activity against human HepG2 cells incubated for 48 hrs by MTT assay
    Cytotoxic activity against human HepG2 cells incubated for 48 hrs by MTT assay
    [PMID: 28587825]
    HepG2 IC50
    0.94 μM
    Compound: 1
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    [PMID: 34256125]
    HepG2 IC50
    1.3 μM
    Compound: PC1
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 32717483]
    HepG2 IC50
    1.33 μM
    Compound: CE
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 31051401]
    HepG2 IC50
    1.5 μM
    Compound: CEL
    Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    [PMID: 35536757]
    HepG2 IC50
    1.62 μM
    Compound: 1; CEL
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    [PMID: 30316059]
    HepG2 IC50
    3.18 μM
    Compound: CEL
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    [PMID: 31725288]
    HepG2 IC50
    3.73 μM
    Compound: Celastrol
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 36274272]
    HepG2 IC50
    4.01 μM
    Compound: 1
    Anticancer activity against human HepG2 cells assessed as cell survival after 48 hrs by MTT assay
    Anticancer activity against human HepG2 cells assessed as cell survival after 48 hrs by MTT assay
    [PMID: 25812966]
    HepG2 IC50
    6.17 μM
    Compound: Celastrol
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    [PMID: 29486954]
    HOS IC50
    0.93 μM
    Compound: 1; CEL
    Antiproliferative activity against human HOS cells after 48 hrs by MTT assay
    Antiproliferative activity against human HOS cells after 48 hrs by MTT assay
    [PMID: 30316059]
    HOS IC50
    1.46 μM
    Compound: CEL
    Antiproliferative activity against human HOS cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HOS cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    [PMID: 31725288]
    HT-1080 ED50
    0.5 μg/mL
    Compound: 3
    Cytotoxicity against human HT1080 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human HT1080 cells after 48 hrs by sulforhodamine B assay
    [PMID: 8158155]
    HT-29 IC50
    0.6 μM
    Compound: CEL
    Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay
    [PMID: 35290844]
    HT-29 IC50
    1.28 μM
    Compound: 1
    Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
    [PMID: 28865279]
    HT-29 IC50
    1300 ng/mL
    Compound: 5
    Cytotoxicity against human HT-29 cells after 72 hrs by Alamar blue assay
    Cytotoxicity against human HT-29 cells after 72 hrs by Alamar blue assay
    [PMID: 9644053]
    Huh-7 IC50
    4.45 μM
    Compound: Celastrol
    Antiproliferative activity against human Huh-7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human Huh-7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 36274272]
    KB ED50
    0.2 μg/mL
    Compound: 6
    Cytotoxicity against human KB cells after 3 days by SRB assay
    Cytotoxicity against human KB cells after 3 days by SRB assay
    [PMID: 14640511]
    KB IC50
    1.7 μM
    Compound: Celastrol
    Antiproliferative activity against human KB cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    Antiproliferative activity against human KB cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    [PMID: 34170694]
    KB ED50
    2.3 μg/mL
    Compound: 3
    Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay
    [PMID: 8158155]
    KB-V1 ED50
    1.2 μg/mL
    Compound: 3
    Cytotoxicity against human KBV1 cells after 72 hrs by sulforhodamine B assay in presence of vinblastine
    Cytotoxicity against human KBV1 cells after 72 hrs by sulforhodamine B assay in presence of vinblastine
    [PMID: 8158155]
    KB-V1 ED50
    1.7 μg/mL
    Compound: 3
    Cytotoxicity against human KBV1 cells after 72 hrs by sulforhodamine B assay in absence of vinblastine
    Cytotoxicity against human KBV1 cells after 72 hrs by sulforhodamine B assay in absence of vinblastine
    [PMID: 8158155]
    L02 IC50
    0.64 μM
    Compound: CEL
    Antiproliferative activity against human L02 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay
    Antiproliferative activity against human L02 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay
    [PMID: 35290844]
    L02 IC50
    0.78 μM
    Compound: 1
    Cytotoxicity against human L02 cells assessed as cell viability measured after 72 hrs by MTT assay
    Cytotoxicity against human L02 cells assessed as cell viability measured after 72 hrs by MTT assay
    [PMID: 34256125]
    L02 IC50
    0.83 μM
    Compound: CEL
    Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    [PMID: 34968902]
    L02 IC50
    1.12 μM
    Compound: Celastrol
    Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 36274272]
    L02 IC50
    1.94 μM
    Compound: PC1
    Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 32717483]
    LN-229 IC50
    3.13 μM
    Compound: CEL
    Antiproliferative activity against human LN-229 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    Antiproliferative activity against human LN-229 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    [PMID: 34968902]
    LNCaP ED50
    0.6 μg/mL
    Compound: 3
    Cytotoxicity against human LNCAP cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human LNCAP cells after 72 hrs by sulforhodamine B assay
    [PMID: 8158155]
    Lu1 ED50
    1.3 μg/mL
    Compound: 3
    Cytotoxicity against human Lu1 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human Lu1 cells after 72 hrs by sulforhodamine B assay
    [PMID: 8158155]
    MCF7 IC50
    0.153 μM
    Compound: 2
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTS/PMS assay
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTS/PMS assay
    [PMID: 25756299]
    MCF7 ED50
    0.21 μg/mL
    Compound: 6
    Cytotoxicity against human MCF7 cells after 3 days by SRB assay
    Cytotoxicity against human MCF7 cells after 3 days by SRB assay
    [PMID: 14640511]
    MCF7 IC50
    1.06 μM
    Compound: CE
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 31051401]
    MCF7 IC50
    1.2 μM
    Compound: Celastrol
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    [PMID: 34170694]
    MCF7 IC50
    1.35 μM
    Compound: 1
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    [PMID: 28865279]
    MCF7 IC50
    1.56 μM
    Compound: 1; CEL
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    [PMID: 30316059]
    MCF7 IC50
    1.7 μM
    Compound: CEL
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    [PMID: 35536757]
    MCF7 IC50
    2.04 μM
    Compound: CEL
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    [PMID: 31725288]
    MCF7 IC50
    2.13 μM
    Compound: Celastrol
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 27647369]
    MCF7 IC50
    2.23 μM
    Compound: CEL
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay
    [PMID: 35290844]
    MCF7 IC50
    6.84 μM
    Compound: Celastrol
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    [PMID: 29486954]
    MDA-MB-231 IC50
    0.9 μM
    Compound: Celastrol
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay
    [PMID: 34170694]
    MDA-MB-231 IC50
    1.08 μM
    Compound: Celastrol
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 36274272]
    MDA-MB-231 IC50
    1.32 μM
    Compound: 1
    Antiproliferative activity against human MDA-MB-231cells after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231cells after 72 hrs by MTT assay
    [PMID: 28865279]
    MDA-MB-231 IC50
    1.32 μM
    Compound: 1
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    [PMID: 28688281]
    MDA-MB-231 IC50
    1.98 μM
    Compound: CEL
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    [PMID: 35238566]
    Mesenchymal stem cells IC50
    0.7 μM
    Compound: Celastrol
    Cytotoxicity against human mesenchymal bone marrow stem cells measured after 48 hrs by MTT assay
    Cytotoxicity against human mesenchymal bone marrow stem cells measured after 48 hrs by MTT assay
    [PMID: 34170694]
    MGC-803 IC50
    0.78 μM
    Compound: 1
    Inhibition of telomerase in human MGC803 cell extracts after 24 hrs by TRAP-PCR-ELISA
    Inhibition of telomerase in human MGC803 cell extracts after 24 hrs by TRAP-PCR-ELISA
    [PMID: 25812966]
    MGC-803 IC50
    1.55 μM
    Compound: 1
    Anticancer activity against human MGC803 cells assessed as cell survival after 48 hrs by MTT assay
    Anticancer activity against human MGC803 cells assessed as cell survival after 48 hrs by MTT assay
    [PMID: 25812966]
    MIA PaCa-2 IC50
    0.46 μM
    Compound: 1
    Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by MTT assay
    [PMID: 28865279]
    MIA PaCa-2 IC50
    0.46 μM
    Compound: 1
    Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by MTT assay
    [PMID: 28688281]
    MRC5 IC50
    4.4 μM
    Compound: CEL
    Cytotoxicity against human MRC5 cells assessed as inhibition of cell growth measured after 96 hrs by MTT assay
    Cytotoxicity against human MRC5 cells assessed as inhibition of cell growth measured after 96 hrs by MTT assay
    [PMID: 35255689]
    NCI-H460 IC50
    12.3 μM
    Compound: Celastrol
    Cytotoxicity against human NCI-H460 cells after overnight incubation by MTT assay
    Cytotoxicity against human NCI-H460 cells after overnight incubation by MTT assay
    [PMID: 21942765]
    OVCAR-3 IC50
    1.93 μM
    Compound: Celastrol
    Antiproliferative activity against human OVCAR3 cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human OVCAR3 cells incubated for 48 hrs by MTT assay
    [PMID: 31279299]
    P388 ED50
    3.5 μg/mL
    Compound: 3
    Cytotoxicity against mouse P388 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against mouse P388 cells after 48 hrs by sulforhodamine B assay
    [PMID: 8158155]
    PANC-1 IC50
    2.48 μM
    Compound: Celastrol
    Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    [PMID: 27647369]
    PANC-1 IC50
    3 μM
    Compound: 44
    Antiproliferative activity against human PANC1 cells after 24 hrs by MTS assay
    Antiproliferative activity against human PANC1 cells after 24 hrs by MTS assay
    [PMID: 31663736]
    PC-3 ED50
    0.27 μg/mL
    Compound: 6
    Cytotoxicity against human PC3 cells after 3 days by SRB assay
    Cytotoxicity against human PC3 cells after 3 days by SRB assay
    [PMID: 14640511]
    PC-3 IC50
    1.68 μM
    Compound: CEL
    Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay
    Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay
    [PMID: 35290844]
    QGY-7703 IC50
    2.43 μM
    Compound: PC1
    Antiproliferative activity against human QGY-7703 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human QGY-7703 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 32717483]
    RAW264.7 IC50
    > 50 μM
    Compound: 5
    Cytotoxicity against mouse RAW264.7 cells after 18 hrs by MTT assay
    Cytotoxicity against mouse RAW264.7 cells after 18 hrs by MTT assay
    [PMID: 22705020]
    RAW264.7 IC50
    0.2 μM
    Compound: 5
    Inhibition of LPS-stimulated NFkappaB activation transfected in mouse RAW264.7 cells after 18 hrs by luciferase reporter gene assay
    Inhibition of LPS-stimulated NFkappaB activation transfected in mouse RAW264.7 cells after 18 hrs by luciferase reporter gene assay
    [PMID: 22705020]
    RAW264.7 IC50
    0.23 μM
    Compound: 7
    Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production treated 3 hrs before LPS challenge assessed after 24 hrs by Griess reagent assay
    Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production treated 3 hrs before LPS challenge assessed after 24 hrs by Griess reagent assay
    [PMID: 11809076]
    RAW264.7 IC50
    0.27 μM
    Compound: 7
    Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NF-kappaB activation treated 3 hrs before LPS challenge assessed after 24 hrs by SEAP reporter gene assay
    Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NF-kappaB activation treated 3 hrs before LPS challenge assessed after 24 hrs by SEAP reporter gene assay
    [PMID: 11809076]
    RAW264.7 IC50
    0.3 μM
    Compound: Celastrol
    Inhibition of LPS-induced NF-kappaB activation in mouse RAW264.7 cells by SEAP reporter gene assay
    Inhibition of LPS-induced NF-kappaB activation in mouse RAW264.7 cells by SEAP reporter gene assay
    [PMID: 18841906]
    RAW264.7 IC50
    0.8 μM
    Compound: Celastrol
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha production incubated for 24 hrs by ELISA
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha production incubated for 24 hrs by ELISA
    [PMID: 23234407]
    RAW264.7 IC50
    1 μM
    Compound: Celastrol
    Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method
    Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method
    [PMID: 29730029]
    RAW264.7 IC50
    1 μM
    Compound: Celastrol
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method
    [PMID: 23127886]
    RAW264.7 IC50
    1 μM
    Compound: Celastrol
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by griess assay
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by griess assay
    [PMID: 22024033]
    RAW264.7 IC50
    1 μM
    Compound: Celastrol
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess reagent method
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess reagent method
    [PMID: 21978676]
    RAW264.7 IC50
    1 μM
    Compound: Celastrol
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide generation incubated for 24 hrs
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide generation incubated for 24 hrs
    [PMID: 23234407]
    RAW264.7 IC50
    1 μM
    Compound: Celastrol
    Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by Griess reaction based method
    Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by Griess reaction based method
    [PMID: 25637363]
    SGC-7901 IC50
    0.15 μM
    Compound: 1
    Anticancer activity against human SGC7901 cells assessed as cell survival after 48 hrs by MTT assay
    Anticancer activity against human SGC7901 cells assessed as cell survival after 48 hrs by MTT assay
    [PMID: 25812966]
    SGC-7901 IC50
    0.87 μM
    Compound: Celastrol
    Cytotoxic activity against human SGC7901 cells incubated for 48 hrs by MTT assay
    Cytotoxic activity against human SGC7901 cells incubated for 48 hrs by MTT assay
    [PMID: 28587825]
    SK-BR-3 IC50
    0.72 μM
    Compound: 1
    Antiproliferative activity against human SKBR3 cells after 72 hrs by MTT assay
    Antiproliferative activity against human SKBR3 cells after 72 hrs by MTT assay
    [PMID: 28688281]
    SK-MEL-2 ED50
    0.6 μg/mL
    Compound: 3
    Cytotoxicity against human SK-MEL-2 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human SK-MEL-2 cells after 72 hrs by sulforhodamine B assay
    [PMID: 8158155]
    SK-N-SH CC50
    1.6 μM
    Compound: Celastrol
    Cytotoxicity against human SK-N-SH cells after 72 hrs by MTS assay
    Cytotoxicity against human SK-N-SH cells after 72 hrs by MTS assay
    [PMID: 19502057]
    SK-OV-3 IC50
    1.16 μM
    Compound: 1
    Antiproliferative activity against human SKOV3 cells after 72 hrs by MTT assay
    Antiproliferative activity against human SKOV3 cells after 72 hrs by MTT assay
    [PMID: 28865279]
    SK-OV-3 IC50
    1.16 μM
    Compound: 1
    Antiproliferative activity against human SKOV3 cells after 72 hrs by MTT assay
    Antiproliferative activity against human SKOV3 cells after 72 hrs by MTT assay
    [PMID: 28688281]
    SK-OV-3 IC50
    1.68 μM
    Compound: Celastrol
    Antiproliferative activity against human SKOV3 cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human SKOV3 cells incubated for 48 hrs by MTT assay
    [PMID: 31279299]
    SMMC-7721 IC50
    0.58 μM
    Compound: 1
    Anticancer activity against human SMMC7721 cells assessed as cell survival after 48 hrs by MTT assay
    Anticancer activity against human SMMC7721 cells assessed as cell survival after 48 hrs by MTT assay
    [PMID: 25812966]
    SMMC-7721 IC50
    1.07 μM
    Compound: PC1
    Antiproliferative activity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 32717483]
    SMMC-7721 IC50
    6.04 μM
    Compound: Celastrol
    Antiproliferative activity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    [PMID: 36274272]
    T cell line CC50
    0.1 μM
    Compound: Celastrol
    Cytotoxicity against BALB/c mouse T cell assessed as reduction in cell viability after 48 hrs by CCK8 assay
    Cytotoxicity against BALB/c mouse T cell assessed as reduction in cell viability after 48 hrs by CCK8 assay
    [PMID: 32822186]
    T cell line IC50
    83 nM
    Compound: Celastrol
    Antiproliferative activity against Con A-induced BALB/c mouse T cell after 48 hrs by CCK8 assay
    Antiproliferative activity against Con A-induced BALB/c mouse T cell after 48 hrs by CCK8 assay
    [PMID: 32822186]
    THP-1 EC50
    15 μM
    Compound: Celastrol
    Induction of apoptosis in TRAIL-resistant human THP1 cells after 24 hrs by annexin-V staining
    Induction of apoptosis in TRAIL-resistant human THP1 cells after 24 hrs by annexin-V staining
    [PMID: 20864342]
    U-251 IC50
    4.43 μM
    Compound: CEL
    Antiproliferative activity against human U-251 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    Antiproliferative activity against human U-251 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    [PMID: 34968902]
    U2OS IC50
    1.86 μM
    Compound: CEL
    Antiproliferative activity against human U2OS cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human U2OS cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    [PMID: 35238566]
    U-373MG ATCC ED50
    0.4 μg/mL
    Compound: 3
    Cytotoxicity against human U373 cells after 96 hrs by sulforhodamine B assay
    Cytotoxicity against human U373 cells after 96 hrs by sulforhodamine B assay
    [PMID: 8158155]
    U-87MG ATCC ED50
    0.22 μg/mL
    Compound: 6
    Cytotoxicity against human U87MG cells after 3 days by SRB assay
    Cytotoxicity against human U87MG cells after 3 days by SRB assay
    [PMID: 14640511]
    U-87MG ATCC IC50
    2.23 μM
    Compound: CEL
    Antiproliferative activity against human U87 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    Antiproliferative activity against human U87 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    [PMID: 34968902]
    ZR-75-1 ED50
    0.3 μg/mL
    Compound: 3
    Cytotoxicity against human ZR-75-1 cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human ZR-75-1 cells after 72 hrs by sulforhodamine B assay
    [PMID: 8158155]
    体外研究
    (In Vitro)

    Celastrol (Tripterine;Tripterin) 以浓度依赖性方式显著抑制 PC-3 细胞中蛋白酶体胰凝乳蛋白酶的活性;在 2.5 μM 时,它达到约 55% 的抑制,与其对纯化的 20S 蛋白酶体的效力相当 (IC50=2.5 μM)。此外,观察到 IκB-α、Bax 和 p27 水平升高,这是用 Celastrol 处理的 PC-3 细胞中蛋白酶体的三种众所周知的靶蛋白[1]

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    体内研究
    (In Vivo)

    用 Celastrol (1-3 mg/kg/d,腹腔注射,1-31 天) 处理携带 PC-3 肿瘤的裸鼠导致显著抑制肿瘤生长 (65-93%)[1]
    用 3 和 6 mg/kg Celastrol 处理后,丙二醛 (MDA) 水平分别显著降低 35.2% 和 36.7% (P<0.05)。用 3 和 6 mg/kg 的 Celastrol 处理可显著将 GSH 水平 (P<0.05) 恢复到几乎正常的水平[2]

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Clinical Trial
    分子量

    450.61

    Formula

    C29H38O4

    CAS 号
    性状

    固体

    颜色

    Orange to reddish brown

    中文名称

    雷公藤红素;南蛇藤素;南蛇藤醇;苦瓜甙;苦瓜苷;苦瓜素;苦瓜皂甙

    结构分类
    初始来源
    运输条件

    Room temperature in continental US; may vary elsewhere.

    储存方式
    Powder -20°C 3 years
    In solvent -80°C 6 months
    -20°C 1 month
    溶解性数据
    细胞实验: 

    DMSO 中的溶解度 : 33.33 mg/mL (73.97 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

    配制储备液
    浓度 溶剂体积 质量 1 mg 5 mg 10 mg
    1 mM 2.2192 mL 11.0961 mL 22.1921 mL
    5 mM 0.4438 mL 2.2192 mL 4.4384 mL
    查看完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
    储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

    • 摩尔计算器

    • 稀释计算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    质量
    =
    浓度
    ×
    体积
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    浓度 (start)

    C1

    ×
    体积 (start)

    V1

    =
    浓度 (final)

    C2

    ×
    体积 (final)

    V2

    动物实验:

    请根据您的 实验动物和给药方式 选择适当的溶解方案。

    以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
    ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用
    以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

    • 方案 一

      请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (5.55 mM); 澄清溶液

      此方案可获得 ≥ 2.5 mg/mL(饱和度未知)的澄清溶液。

      1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;再向上述体系中加入 50 μL Tween-80,混合均匀;然后再继续加入 450 μL 生理盐水 定容至 1 mL

      生理盐水的配制:将 0.9 g 氯化钠,溶解于 ddH₂O 并定容至 100 mL,可以得到澄清透明的生理盐水溶液。
    动物溶解方案计算器
    请输入动物实验的基本信息:

    给药剂量

    mg/kg

    动物的平均体重

    g

    每只动物的给药体积

    μL

    动物数量

    由于实验过程有损耗,建议您多配一只动物的量
    请输入您的动物体内配方组成:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    如果您的动物是免疫缺陷鼠或者体弱鼠,建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。
    方案所需 助溶剂 包括:DMSO ,均可在 MCE 网站选购。 Tween 80,均可在 MCE 网站选购。
    计算结果
    工作液所需浓度 : mg/mL
    储备液配制方法 : mg 药物溶于 μL  DMSO(母液浓度为 mg/mL)。
    您所需的储备液浓度超过该产品的实测溶解度,以下方案仅供参考,如有需要,请与 MCE 中国技术支持联系。
    动物实验体内工作液的配制方法 : 取 μL DMSO 储备液,加入 μL  μL ,混合均匀至澄清,再加 μL Tween 80,混合均匀至澄清,再加 μL 生理盐水
    连续给药周期超过半月以上,请谨慎选择该方案。
    请确保第一步储备液溶解至澄清状态,从左到右依次添加助溶剂。您可采用超声加热 (超声清洗仪,建议频次 20-40 kHz),涡旋吹打等方式辅助溶解。
    纯度 & 产品资料

    纯度: 99.90%

    参考文献
    Kinase Assay
    [1]

    A purified rabbit 20S proteasome (0.1 μg) is incubated with 40 μM of various fluorogenic peptide substrates in 100 μL assay buffer (20 mM Tris-HCl ,pH 7.5), in the presence of Celastrol or Oridonin at different concentrations or in the solvent DMSO for 2 hours at 37°C, followed by measurement of inhibition of each proteasomal activity[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Assay
    [1]

    Prostate cancer cells (5,000-8,000) are plated in each well of a 96-well plate and then treated with either DMSO, Celastrol, or Oridonin at different concentrations for 12 to 16 hours, followed by an additional 2-hour incubation with Z-Gly-Gly-Leu-AMC (at 40 μM). After that, the proteasome activity is measured using the whole plate[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [1][2]

    Mice[1]
    Male nude immunodeficient mice NCRNU-M, aged 5 weeks, are used. On day 0, human prostate cancer PC-3 or C4-2B cells (5-10×106) suspended in 0.1 mL of serum-free RPMI 1640 are inoculated s.c. in the right flank of each mouse (four mice per group). For the first experiment using PC-3 cells, on day 14 after inoculation, the animals started daily i.p. injection with either 50 to 100 μL of a vehicle [10% DMSO, 70% Cremophor/ethanol (3:1), and 20% PBS], and 1.0 or 3.0 mg/kg of Celastrol. Tumor sizes are measured daily using calipers and their volumes are calculated using a standard formula: width2×length/2. Body weight is measured weekly. To study whether the proteasome is inhibited in an early phase of the experiment, after 3 days of treatment, one control and one 3.0 mg/kg Celastrol -treated mouse is sacrificed. The rest are sacrificed after 16 days of treatment when control tumors reach 1,400 mm3. For the second PC-3 tumor experiment, 12 days after inoculation, mice are randomly divided into three groups and treated with either control, Celastrol, or Oridonin at 1.5 mg/kg daily for the duration of the study (31 days). In another experiment, to study the effects of Celastrol on AR expression, nude mice bearing C4-2B tumors receive daily i.p. injection of the vehicle or 3.0 mg/kg Celastrol.
    Rats[2]
    Male Sprague-Dawley (SD) rats (n=90, 6 weeks old), weighing 161±9 g, are randomly divided into the control (NC) and the high energy diet (HED) groups. In the control group, the animals receive a standard chow diet, while the rats in the HED group are fed with an additional high energy emulsion. After 8 weeks on their respective diets, Streptozotocin (STZ; 45 mg/kg) dissolved in 0.1 mol/l citrate buffer (pH 4.5) is injected into the caudal vein of the rats in the HED group to establish a model of T2DM, while the rats in the control group are injected with sodium citrate buffer. The rats with blood glucose levels ≥16.7 mM at 7 days after the STZ injection are selected as the model of diabetes. On average, 80% of the rats injected with STZ met these criteria. At 1 week following the injection of STZ, the rats with successfully-induced diabetes are randomly divided into the diabetes model (DM) group, the Celastrol low-dose group (1 mg/kg/day), the Celastrol middle-dose group (3 mg/kg/day) and the Celastrol high-dose group (6 mg/kg/day) (n=15 rats per group). The rats in the treatment groups are administered Celastrol by gavage, whereas the rats in the NC and DM groups are administered an equal amount of distilled water (2 mL). Following 8 weeks of the respective treatments, rats are anesthetized with an intraperitoneal injection of sodium pentobarbital (30 mg/kg body weight) and tissue samples are collected for analysis. The paravertebral muscle is excised from the rat bodies, and is cut perpendicularly along the longitudinal axis and fixed in phosphate-buffered 20% formaldehyde. Histological paraffin-embedded sections (5 μm) are then prepared for H&E staining. The sections of paravertebral muscle are snap-frozen in liquid nitrogen and stored at ?80°C until further analysis.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    参考文献

    完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
    储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

    可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.2192 mL 11.0961 mL 22.1921 mL 55.4804 mL
    5 mM 0.4438 mL 2.2192 mL 4.4384 mL 11.0961 mL
    10 mM 0.2219 mL 1.1096 mL 2.2192 mL 5.5480 mL
    15 mM 0.1479 mL 0.7397 mL 1.4795 mL 3.6987 mL
    20 mM 0.1110 mL 0.5548 mL 1.1096 mL 2.7740 mL
    25 mM 0.0888 mL 0.4438 mL 0.8877 mL 2.2192 mL
    30 mM 0.0740 mL 0.3699 mL 0.7397 mL 1.8493 mL
    40 mM 0.0555 mL 0.2774 mL 0.5548 mL 1.3870 mL
    50 mM 0.0444 mL 0.2219 mL 0.4438 mL 1.1096 mL
    60 mM 0.0370 mL 0.1849 mL 0.3699 mL 0.9247 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的产品:

    Your information is safe with us. * Required Fields.

       产品名称:

     

    * 需求量:

    * 客户姓名:

     

    * Email:

    * 电话:

     

    * 公司或机构名称:

       留言给我们:

    Bulk Inquiry

    Inquiry Information

    产品名称:
    Celastrol
    目录号:
    HY-13067
    需求量: